MEPAN syndrome

MEPAN syndrome
Other namesMitochondrial enoyl CoA reductase protein-associated neurodegeneration syndrome; MECR-related neurologic disorder; Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities (DYTOABG); Autosomal recessive childhood-onset dystonia, DYT29 type; Childhood-onset generalized dystonia-optic atrophy syndrome; DYT29; Dystonia 29
Ribbon diagram of mitochondrial trans-2-enoyl-CoA reductase (MECR)
SpecialtyMedical genetics
Usual onsetChildhood, Infancy
CausesPathogenic biallelic variants in the MECR gene
Diagnostic methodMolecular genetic testing
Frequency<1:1,000,000

Mitochondrial enoyl reductase protein-associated neurodegeneration (MePAN, MEPAN), also known as MEPAN syndrome, is a rare genetic mitochondrial metabolic disorder. It typically presents in early childhood with dystonia, optic atrophy, and basal ganglia signal abnormalities, although an LHON-like optic neuropathy presentation has also been reported. The disorder is caused by pathogenic variants in the MECR gene, which encodes mitochondrial trans-2-enoyl-CoA reductase (MECR), the enzyme responsible for the last step of mitochondrial fatty acid synthesis (mtFAS). MEPAN was first described by Heimer et al. in 2016.